What we do not know, and what we  must know about the molecular testing  screening in infections transmitted by  infection in mexican blood donors

Héctor A Baptista-González

2009, Number 1

<< Back

Rev Mex Med Transfus 2009; 2 (1)

What we do not know, and what we must know about the molecular testing screening in infections transmitted by infection in mexican blood donors

Baptista-González HA

Full text

How to cite this article

Language: Spanish
References: 21
Page: 30-40
PDF size: 164.75 Kb.

ABSTRACT

The algorithms to screening the blood donors are based primarily on serologic tests by immunoenzyme techniques, mainly ELISA, comprise of the most rational scheme and with a better result cost-effectiveness reason why using is the methodology more. In order to be able to include a new test in the screening of blood donors, we must complete compulsorily, certain epidemiologists and technicians criteria to be able to obtain a favorable impact on modification of natural history of the disease, to obtain the feasibility and viability of intervention evaluated by an integrative study of favorable cost-efficiency. The additional tests (p24, anti-HBc) or molecular techniques have generated an added value in this process of screening with variable results. Sufficient information that does not exist it demonstrates in scientific technical terms, like other interventions in health, the advantages of the molecular studies by a universal strategy in testing blood donors. The knowledge of the process to study blood donors, and the persistent reports of the high seroprevalence, indicate to evident faults in tactically important points of education for the health, promotion of blood donation and medical evaluation in the selection of blood donors, in an inefficient legal frame that inhibits the development of safe donor, so that altogether with his results of cost-efficiency, it settles down a coherent sequence between safe donor, and safe blood to the benefit of population health.

REFERENCES

Schmunis G, Cruz RJ. Safety of the blood supply in Latino America. Clin Microbiol Rev 2005; 18: 12-29.
Schmidt M, Nubling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang 2006; 91: 237-243.
Allain JP. International collaborative study proposal for the characterization of occult hepatitis B virus infection identified by nucleic acid or anti-HBc screening. Vox Sang 2007; 92: 254-257.
Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang 2006; 90: 77-84.
Kessler HH. Comparison of currently avaible assays for detection of hepatitis B virus DNA in the routine diagnostic laboratory. Expert Rev Mol Diagn 2005; 5: 531-536.
Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K et al. HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005; 88: 77-86.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M. Polish Blood Transfusion Service Viral Study Group. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 2006; 44: 1666-1674.
Kretzschmar E, Chudy M, Nübling CM, Ross RS, Kruse F, Trobisch H. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007; 92: 297-301.
Cheng KY, Chang CD, Salbilla VA, Kirchhoff LV, Leiby DA, Schochetman G et al. Immunoblot assay using recombinant antigens as a supplemental test to confirm the presence of antibodies to Trypanosoma cruzi. Clin Vaccine Immunol. 2007; 14: 355-361.
Komar N, Clark GG. West Nile virus activity in Latin America and the Caribbean. Rev Panam Salud Publica 2006; 19: 112-117.
Chalker VJ, Rossouw A, Mee Z, Patel P, Vaughan H, James VL. External quality assessment for the molecular detection of Hepatitis C virus. J Clin Virol 2007; 39:141-144.
Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 22-31.
Fytili P, Tiemann C, Wang C, Schulz S, Schaffer S, Manns MP et al. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol 2007; 39: 308-311.
Pisani G, Marino F, Cristiano K, Bisso GM, Mele C, Luciani F, Wirz M et al. Collaborative study for the calibration of HCV RNA, HBV DNA and HIV RNA reference preparations against the relative international standards. Ann Ist Super Sanita 2007; 43: 69-76.
Hsia CC, Chizhikov VE, Yang AX, Selvapandiyan A, Hewlett I, Duncan R et al. Microarray multiplex assay for the simultaneous detection and discrimination of hepatitis B, hepatitis C, and human immunodeficiency type-1 viruses in human blood samples. Biochem Biophys Res Commun 2007; 356: 1017-1023.
Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006; 91: 1-12.
Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diagn Ther 2006; 10: 77-91.
Ly TD, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods 2007; 143: 86-94.
20.Wiedmann M, Kluwick S, Walter M, Fauchald G, Howe J, Bronold M et al. HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas ((R)) TaqScreen MPX test in seroconverting donors. J Clin Virol 2007; 39: 282-287.
Katsoulidou A, Moschidis Z, Sypsa V, Chini M, Papatheodoridis GV, Tassopoulos NC et al. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load. Vox Sang 2007; 92: 8-14.